Last reviewed · How we verify
Soy isoflavone supplement
The Soy isoflavone supplement, marketed by the American Lung Association Asthma Clinical Research Centers, holds a niche position in the dietary supplement market. A key strength is the protection of its composition through a patent expiring in 2028. The primary risk is the lack of clear primary indication and revenue data, which may limit its market appeal and investment potential.
At a glance
| Generic name | Soy isoflavone supplement |
|---|---|
| Also known as | Soy supplement |
| Sponsor | American Lung Association Asthma Clinical Research Centers |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Soy Tomato Juice to Improve Outcomes in Pancreatitis (PHASE1, PHASE2)
- Prandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein (NA)
- Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study (PHASE2)
- Soy Isoflavonates Versus Placebo on Quality of Life in Menopausal Women (NA)
- Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression (NA)
- High-protein Oral Supplement Improves Normalized Protein Catabolic Rate and Inflammation Markers (NA)
- Soy as an Innovative Dietary Component in Abdominal Obesity Management Amongst Peri- and Early Menopausal Women (NA)
- Assessing the Synergistic Effects of Black Cohosh, Soy Isoflavones, and SDG Lignans (Soloways TM) on Menopausal Symptoms (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: